Combined immunotherapy and cytokine control therapy for cancer treatment

摘要

Compositions disclosed herein, and methods of use thereof, include those for suppressing or reducing the incidence of cytokine release syndrome or cytokine storm in a subject undergoing CAR T cell therapy, wherein the subject has apoptotic cells Alternatively, a composition containing apoptotic cell supernatant is administered. In some cases, the compositions and methods of use disclosed herein do not reduce the effectiveness of CAR T cell cancer therapy. Also disclosed herein are compositions and methods of use thereof for reducing or inhibiting cytokine production in a subject experiencing a cytokine release syndrome or cytokine storm comprising administration of a composition comprising apoptotic cells or apoptotic cell supernatant. Is done. [Selection] Figure 2B